Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.60 |
| ▸ | POLB | P06746 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10410636 | 0.98 | ALDH1A1 (0.58) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL12580051 | 0.81 | ALDH1A1 (0.65) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL14443010 | 0.78 | RAB9A (0.42) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL10245401 | 0.77 | ALDH1A1 (0.60) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL11041715 | 0.77 | ALDH1A1 (0.60) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL6130008 | 0.75 | ALDH1A1 (0.57) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL25279455 | 0.75 | ALDH1A1 (0.50) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL21397712 | 0.74 | ALDH1A1 (0.60) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL140950 | 0.74 | TSHR (0.59) | ALDH1A1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL105281 | 0.73 | MAPT (0.51) | ALDH1A1POLBMAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-4895840-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0295010-A1 | Derivatives of alkylaminoalkyl ureas and cyanoguanidines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-12-14 | — | — | EP | disclosed |
| US-4724235-A | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-09 | — | — | US | disclosed |
| US-4597902-A | TREATMENT OF CARDIAC ARRHYTHMIAS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0066415-B1 | N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0066415-A2 | N-(arylthioalkyl)-N'-(aminoalkyl)ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | ALDH1A1 2611/4885POLB 2352/4885MAPT 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.